Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 4/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756182 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL753813 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL753595 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL140287 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL9663803 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL756049 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL754626 | 1.00 | — | — | |
| SCHEMBL2126479 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL756126 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA | |
| SCHEMBL3925041 | 1.00 | ALDH1A1 (0.69) | ALDH1A1TSHRMAPTDNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547113-B2 | Liquid polymer suspensions | RHODIA OPERATIONS (FR) | 2023-01-10 | — | — | US | claimed |
| EP-2100002-B1 | SCALE SQUEEZE TREATMENT METHODS AND SYSTEMS | RHODIA (US) | 2012-04-25 | — | — | EP | claimed |
| US-11547113-B2 | Liquid polymer suspensions | RHODIA OPERATIONS (FR) | 2023-01-10 | — | — | US | disclosed |
| US-10423084-B2 | Method for producing liquid developer | CANON KABUSHIKI KAISHA (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20190271929-A1 | LIQUID DEVELOPER AND METHOD FOR MANUFACTURING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-09-05 | — | — | US | disclosed |
| US-20190155180-A1 | METHOD FOR PRODUCING LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10175597-B2 | Liquid developer and method of producing same | CANON KABUSHIKI KAISHA (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180348658-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-12-06 | — | — | US | disclosed |
| EP-3410217-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR PRODUCING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-20180329333-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR MANUFACTURING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-11-15 | — | — | US | disclosed |
| EP-3401735-A1 | CURABLE LIQUID DEVELOPER AND METHOD FOR MANUFACTURING CURABLE LIQUID DEVELOPER | CANON KABUSHIKI KAISHA (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20130044168-A1 | INK-JET IMAGE FORMING METHOD AND INK-JET INK SET | KONICA MINOLTA HOLDINGS, INC. (JP) | 2013-02-21 | — | — | US | disclosed |
| US-8349916-B2 | Actinic energy radiation curable ink-jet ink, ink-jet recording method, and printed matter | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2013-01-08 | — | — | US | disclosed |
| EP-2228415-B1 | Actinic energy radiation curable ink-jet ink, ink-jet recoring method, and printed matter | KONICA MINOLTA IJ TECHNOLOGIES (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100255211-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET IMAGE FORMING METHOD | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2236568-A1 | Actinic energy radiation curable ink-jet ink and ink-jet image forming method | Konica Minolta IJ Technologies, Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100239777-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET RECORDING METHOD | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2230283-A1 | Actinic energy radiation curable ink-jet ink and ink-jet recording method | Konica Minolta IJ Technologies, Inc. (JP) | 2010-09-22 | — | — | EP | disclosed |
| US-20100233446-A1 | ACTINIC ENERGY RADIATION CURABLE INK-JET INK, INK-JET RECORDING METHOD, AND PRINTED MATTER | KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2228415-A1 | Acting energy radiation curable ink-jet ink, ink-jet recoring method, and printed matter | Konica Minolta IJ Technologies, Inc. (JP) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10175597-B2 | Liquid developer and method of producing same | AUP1, RCC1, CBR1 | ALDH1A1 1142/4885TSHR 1523/4885MAPT 79/4885 |
| US-11547113-B2 | Liquid polymer suspensions | ALG1, ALG3, MUC1 | ALDH1A1 3367/4885TSHR 4618/4885MAPT 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.